DIABETES: Anti-PCSK9 antibodies — beneficial or inducers of diabetes?

    loading  Checking for direct PDF access through Ovid

Abstract

A recent study has shown that evolocumab, an injectable monoclonal antibody directed against proprotein convertase subtilisin/kexin type 9 (PCSK9), robustly reduces levels of LDL cholesterol and decreases the risk of cardiovascular disease in patients with and without diabetes mellitus. When given on top of statins, evolocumab does not induce diabetes mellitus.

Refers to Sabatine, M. S. et al. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes Endocrinol.http://dx.doi.org/10.1016/S2213–8587(17)30313–3 (2017)

Related Topics

    loading  Loading Related Articles